Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 21, 2019

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts		001-14041		04-2882273
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

400 Wood Road, Braintree, MA		02184
(Address of principal executive offices)		(Zip Code)

  Registrant’s telephone number, including area code: 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $.01 par value per share	HAE	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

---

Item 7.01 Regulation FD Disclosure.

On May 21, 2019, Haemonetics Corporation (the “Company”) completed the sale to CSL Plasma Inc. (“CSL”) of substantially all of the tangible assets held by the Company relating to the manufacture of anti-coagulant and saline at the Company’s Union, South Carolina facility, which consist primarily of property, plant and equipment and inventory, and CSL assumed certain related liabilities, upon the terms previously disclosed in the Company’s Current Report on Form 8-K dated May 14, 2019.

---

SIGNATURES

    

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		HAEMONETICS CORPORATION
Date: May 22, 2019		By:	/s/ William P. Burke
		Name:	William P. Burke
		Title:	Executive Vice President, Chief Financial Officer